1. FDA. Patient preference information – voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling: guidance for industry, food and drug administration staff, and other stakeholders. U.S. Department of Health and Human Services Food and Drug Administration, Center for Devices and Radiological Health and Center for Biologics Evaluation and Research, ed. Available from: http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm446680.pdf2016. Accessed May 25, 2021.
2. EMA. The Patient’s Voice in the Evaluation of Medicines. European Medicines Agency, Stakeholders and Communication Division; 2013. Available from: https://www.ema.europa.eu/en/documents/report/report-workshop-patients-voice-evaluation-medicines_en.pdf. Accessed April 14, 2021
3. US Department of Health and Human Services Food and Drug Administration, Center for Devices and Radiological Health and Center for Biologics Evaluation and Research. Patient preference information—voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling: guidance for industry, food and drug administration staff, and other stakeholders. Available from: https://www.fda.gov/media/92593/download. Accessed May 25, 2021.
4. Dual equipoise shared decision making: definitions for decision and behaviour support interventions
5. Personalised medicine: The cognitive side of patients